There is nothing in small-caps to suggest that they are as frothy as the big-caps.
Putting buy-writes in your investing 'toolbox' seems one route to becoming a better investor in 2020.
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
The group is in position to set up for another run.
Aquestive Therapeutics, Chiasma Inc. and Eton Pharmaceuticals each appear to have good prospects in 2020.
A reversal will come, for sure, but there's just no way to time it with any degree of precision.
Gilead offers a nearly 4% yield and looks ready to return to growth.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
This unloved part of the market has frequently produced some of the biggest gainers within my personal portfolio over the years.
Also, another buy setup is emerging in Nutanix.